Partnership expanded to include a 3-year longitudinal biomarker collaboration studying CD19 CAR T-cell therapy in 20 autoimmune patients in multiple indications

EMERYVILLE, Calif., March 22, 2023 – Kyverna Therapeutics (“Kyverna”), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, announces the expansion of a sponsored research agreement with Kyverna Scientific Advisory Board member Prof. Dr. Schett at Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg. The expanded research partnership includes a 3-year longitudinal biomarker collaboration exploring the mode of action of autologous CD19 CAR T-cell therapy in 20 autoimmune patients treated with CD19 CAR T-cell therapy. The collaboration aims to study the molecular and cellular effects of CD19 CAR T-cell therapy on the B and T cells of patients with Systemic Lupus Erythematosus, Myositis, Scleroderma, and other B cell driven autoimmune diseases.

“We are excited by the opportunity to learn more about the promise of CD19 CAR T-cell therapy in autoimmune disease patients and look forward to expanding our productive collaboration” said Artur Wilhelm, FAU scientist.

Kyverna Therapeutics is a cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna’s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. By offering more than one mechanism for taming autoimmunity, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated. For more information, please visit https://kyvernatx.com. 

Kathy Vincent
Greig Communications
kathy@greigcommunications.com

1. Mougiakakos D, Kronke G, Volkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19‑Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021;385(6):567-569.
2. Schett G, Boeltz S, Müller F, Kleyer A, Völkl S, Aigner M, et al. OP0279 CAR-T Cell Treatment of Refractory Systemic Lupus Erythematosus- Safety and Preliminary Efficacy Data From the First Four Patients. Ann Rheum Dis. 2022;81(Suppl 1):185.
3. Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, et al. CD19-targeted CAR T Cells in Refractory Antisynthetase Syndrome. Lancet. 2023;401(10379):815-818.